Skip to content

The challenges in diagnosing and treating Endometriosis patients

The challenges in diagnosing and treating Endometriosis patients

The challenges in diagnosing and treating Endometriosis patients

The challenges in diagnosing and treating Endometriosis patients

March is Endometriosis Awareness Month and Scailyte is proud to celebrate the achievements of leaders in this field. We’re honoured to have interviewed Dr. Sara Imboden, Senior Consultant of the Gynecological Clinic at Inselspital, who also serves as the responsible physician for the certified specialized Endometriosis clinic of Inselspital.

Dr. Imboden is an active Endometriosis researcher covering a range of clinical topics, from symptomatology to surgical interventions in the context of various gynaecological diseases. She obtained her medical degree in Bern, Switzerland, and completed her residency in surgery and gynaecology in Thun and Bern. She also obtained a research fellowship from the Karolinska Institute in Stockholm, Sweden, in 2017.

We’re thrilled to share our interview with Dr. Imboden, in which she describes dealing with Endometriosis from a clinician’s perspective. Check out the video to learn more about her work and the importance of raising awareness for this chronic condition.

#endometriosisawarenessmonth #endometriosis #research #womenhealth #scailyte #EndoWarrior #1in10

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Scailyte and Visterra Partner to Advance Autoimmune Disease Research

Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...

Read more

Recent News

Precision Medicine and The Future of Genomics Summit 2024

Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...

Read more

Recent News

Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution

In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...

Read more

Recent News

Pitch Nic 2024 at Novartis Campus

We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...

Read more

Recent News

Genomics for Health 2024

Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...

Read more

Recent News

The Year of the AI Nobel

2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...

Read more

Recent News

Life Science Industry Meets Data Science Symposium

Scailyte is thrilled to be part of the LIFE SCIENCE INDUSTRY MEETS DATA SCIENCE symposium organised ...

Read more

Recent News

01 /04

Scailyte and Visterra Partner to Advance Autoimmune Disease Research

Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...

Read more

Precision Medicine and The Future of Genomics Summit 2024

Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...

Read more

Recent News

02 /04

Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution

In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...

Read more

Recent News

03 /04

Pitch Nic 2024 at Novartis Campus

We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...

Read more

Genomics for Health 2024

Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...

Read more

Recent News

04 /04

The Year of the AI Nobel

2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...

Read more

Life Science Industry Meets Data Science Symposium

Scailyte is thrilled to be part of the LIFE SCIENCE INDUSTRY MEETS DATA SCIENCE symposium organised ...

Read more

Recent News